GC Green Cross Builds AI-Based Vaccine Production Quality Control System
AI TIMES ·
✦ AI Summary
According to AI TIMES, GC Green Cross was finally selected on September 8 as the lead research institution for a project to develop an AI-ba…
According to AI TIMES, GC Green Cross was finally selected on September 8 as the lead research institution for a project to develop an AI-based vaccine manufacturing and quality management system, overseen by the Ministry of Trade, Industry and Energy and KEIT. The project will run through 2030, and the company plans to build an AI-driven quality control system that manages variability across the entire manufacturing process for mRNA-LNP vaccines, using its Hwasun production infrastructure as the base. A major pillar of the project is building a smart manufacturing and quality management ecosystem together with partner research institutions. The core idea is to combine AI with GMP operations to reduce fluctuations at each process stage and keep quality more consistent. To that end, the company plans to link process analytical technology with AI models to establish real-time quality prediction and anomaly detection systems. The company sees this digital manufacturing foundation as a basis for supplying vaccines more quickly and stably in future infectious disease crises.
Perspective
This selection shows that vaccine production is shifting beyond R&D competition and into competition over manufacturing data and quality consistency. In particular, if a system that reduces variability in the production process takes hold, both supply stability and response speed could improve, making it increasingly likely that the industry will view AI as a core tool for process operations.
This perspective is BizCrush's own commentary and is not part of the reporting by AI TIMES.
This article was produced with the help of an automated content generation algorithm.
Source: AI TIMES
View originalThis article was summarized and organized by BizCrush based on the original article from AI TIMES. For exact quotations and full details, please refer to the original article.